All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Catch up with our live Twitter coverage from the Tandem Meetings Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® 2023
Impact of allo-HSCT and Fried’s frailty phenotype in older patients with AML
We summarize a study assessing the benefits of allo-HSCT in older patients with AML and a study evaluating the impact of Fried’s frailty phenotype on survival outcomes...
Orca-T in patients undergoing allo-HSCT for hematologic malignancies
In this article, we report recent data from two trials on Orca-T in the treatment of patients with hematologic malignancies, both in the matched and 7/8 mismatched donor setting.
Subscribe to get the best content related to AML delivered to your inbox